Nulojix (belatacept): Extension of the temporary restriction in supply up until 4Q 2021 (initiated in March 2017)

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Nulojix
Active substance
belatacept
Therapeutic area (MeSH)
  • Graft Rejection
  • Kidney Transplantation
DHPC type
Medicine shortage
Human ATC code
L04AA28
Dissemination date
23/09/2020

How useful was this page?

Add your rating